Humacyte Inc (HUMA) financials
Humacyte revenue and earnings by year
Humacyte's revenue was $2.04 million in the fiscal year to December 31, 2025, up 30.2% from the year before. Net income was -$40.8 million, -2003.6% of revenue. Since the fiscal year to December 31, 2019, revenue has shrunk 16.9% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 5 fiscal years
| Fiscal year to | Dec 2025 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Revenue | 2 | 2 | 1 | 1 | 6 |
| Revenue growth | 30.2% | 23.9% | -15.3% | -75.9% | — |
| Operating income | -108 | -85 | -81 | -65 | -86 |
| Operating margin | -5306.0% | -5404.3% | -6429.8% | -4332.7% | -1385.0% |
| Net income | -41 | -12 | -26 | -67 | -85 |
| Net margin | -2003.6% | -764.5% | -2096.4% | -4461.7% | -1380.7% |
| Diluted EPS | -$0.26 | -$0.12 | -$0.66 | — | — |
| Free cash flow | -106 | -72 | -81 | -56 | -80 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open HUMA in Markets.
See also: HUMA returns
No forecast, no recommendation. This page describes Humacyte Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.